XenImmune Therapeutics
XenImmune Therapeutics is developing a novel antibody-enzyme fusion to target tumors and trigger the robust immune response known as hyper-acute rejection.
Location: Armonk, NY
Foundation Cornell Technology Licensed: 2022
The Center for Technology Licensing (CTL) is Cornell University's technology transfer office. We manage technology for Cornell's Ithaca campus, Weill Cornell Medicine, Cornell Tech, and Cornell AgriTech in Geneva.